Improvement of the efficiency of treatment in patients with coronary artery disease and metabolic syndrome after percutaneous coronary intervention for acute coronary syndrome without ST-segment elevation.

Authors

  • N. V. Chumachenko

DOI:

https://doi.org/10.26641/2307-0404.2016.2.72151

Keywords:

percutaneous coronary intervention, metabolic syndrome, Quercetin

Abstract

The paper presents original data on improvement of effectiveness of treatment (reduction of systemic inflammation, stabilization of lipid metabolism, improvment of quality of life) in patients with coronary artery disease  (CAD) and metabolic syndrome (MS), who underwent primary percutaneous coronary intervention (PCI) for acute coronary syndrome without ST-segment elevation (ACS nST) by adding quercetin to basic therapy, 40 mg 3 times a day during the 12,07 ± 1,51 months. The reduction of a high sensitive C-reactive proteins (hs-CRP), (2,51 ± 0,93, nmol / L., versus 3,12 ± 0,43, nmol / L.), (p = 0,0007) and low-density lipoproteins (LDL), (4,01 ± 0,36, mmol / L., versus 4,29 ± 0,71, mmol / L.), (p=0,049) in the main group II (n = 33) as compared with the control group I (n=31), respectively,as well as thrombin: 5,96 ± 1,89, ng / mL. in group I as compared with 3,91 ± 1,43, ng / mL. in group II, (p=0,0002) was revealed. High density lipoproteins (HDL) were significantly greater (p = 0,049) in the group II (1,35 ± 0,41, mmol / L.) in comparison with the group I (1,17 ± 0,34, mmol / L.).

Author Biography

N. V. Chumachenko

Odessa National Medical University
Department propedeutics of internal diseases and therapy
Valihovskyy Lane, 2, Odessa, 65000, Ukraine

References

Bratus' VV, Taleva TV, Shumakov VA. [Obesity, in¬sulin resistance, metabolic syndrome: basic and clinical as¬pects]. 2nd ed. Kiev: Chetverta khvilya; 2009;416. Russian.

Dogolіch OІ, Voloshin OІ. [Flavonoid quercetin as a means of preventing cardiovascular risk in patients with gout with high comorbidity]. Fіtoterapіya. Chasopis. 2014;4:88-90. Ukrainian.

Dolzhenko MN. [On the question of the ap-propriateness of metabolic cardioprotection in an era of evidence-based medicine]. Zhurnal suchasnogo lіkarja. 2012;2(3):3-6. Russian.

Kakorin SV, Kononec EN. [Clinical case of acute coronary syndrome in patients with diabetes type 2]. Medicinskij sovet. 2015;8:22-30. Russian.

Shumakova VO, Parhomenko OM, editors. [The recommendations of the Ukrainian Association of Car-diologists for the treatment of patients with acute co-ronary syndrome without persistent ST-segment ele-vation]. Kiev: Chetverta hvilja; 2013;50. Ukrainian.

Tarahovskij JuS, Kim JuA, Abdrasilov BS, Muzafarov EN. [Flavonoids: biochemistry, biophysics, medicine]. Pushhino: Sunchrobook. 2013;311. Russian.

Shhegol'kov AM, Jaroshenko VP, Shakula AV. [Comprehensive medical rehabilitation of patients with myocardial infarction in the functional and recovery period with the inclusion of bioflavonoids]. Lechashhij vrach. 2010;4:77-81. Russian.

Anselmino M, Malmberg K, Ryden L, Ohrvik J. A gluco-metabolic risk index with cardiovascular risk stratification potential in patients with coronary artery disease. Diab Vasc Dis Res. 2009;6(2):62-70.

Ozyazicioglu A, Yalcinskaya S, Vural A, Yumun G, Bozkurt O. Effects of metabolic syndrome on early mortality and morbidity in coronary artery bypass graft patients. J Int Med Res. 2010;38(1):202-7.

Grundy S, Brewer H, Cleeman J, Smith S, Len¬fant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute. American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-8.

Metabolic Syndrome: New Insights for the Healthcare Professional: 2013 Edition. Q. Ashton Acton, editor. Atlanta: ScholarlyEditions. 2013;115.

Mosawy S. Effect of the flavonol quercetin on human platelet function: a review. Food and Public Health. 2015;5(1):1-9.

Berghammer M, Karlsson J, Ekman I, Eriksson P, Dellborg M. Self-reported health status (EQ-5D) in adults with congenital heart disease. Int J Cardiol. 2013;165:537-43.

Soares R, Costa C. Oxidative Stress, Inflam-mation and Angiogenesis in the Metabolic Syndrome. Porto: Springer Science & Business Media. 2009;210.

Tsimikas S, Willerson J, Ridker P. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol. 2006;47:19-31.

Downloads

Published

2016-05-31

How to Cite

1.
Chumachenko NV. Improvement of the efficiency of treatment in patients with coronary artery disease and metabolic syndrome after percutaneous coronary intervention for acute coronary syndrome without ST-segment elevation. Med. perspekt. [Internet]. 2016May31 [cited 2024May18];21(2):52-6. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/72151

Issue

Section

CLINICAL MEDICINE